Neuropace/$NPCE
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Neuropace
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
Ticker
$NPCE
Sector
Primary listing
Employees
209
Headquarters
Website
Neuropace Metrics
BasicAdvanced
$465M
-
-$0.66
1.87
-
Price and volume
Market cap
$465M
Beta
1.87
52-week high
$18.98
52-week low
$7.56
Average daily volume
205K
Financial strength
Current ratio
5.281
Quick ratio
4.252
Long term debt to equity
361.095
Total debt to equity
372.219
Interest coverage (TTM)
-2.19%
Profitability
EBITDA (TTM)
-16.1
Gross margin (TTM)
77.23%
Net profit margin (TTM)
-21.47%
Operating margin (TTM)
-16.34%
Revenue per employee (TTM)
$480,000
Management effectiveness
Return on assets (TTM)
-10.20%
Return on equity (TTM)
-158.74%
Valuation
Price to revenue (TTM)
4.523
Price to book
24.38
Price to tangible book (TTM)
24.38
Price to free cash flow (TTM)
-39.886
Free cash flow yield (TTM)
-2.51%
Free cash flow per share (TTM)
-0.346
Growth
Revenue change (TTM)
25.13%
Earnings per share change (TTM)
-29.60%
3-year revenue growth (CAGR)
29.99%
3-year earnings per share growth (CAGR)
-30.02%
What the Analysts think about Neuropace
Analyst ratings (Buy, Hold, Sell) for Neuropace stock.
Neuropace Financial Performance
Revenues and expenses
Neuropace Earnings Performance
Company profitability
Neuropace News
AllArticlesVideos
NeuroPace to Present at the Leerink Global Healthcare Conference
Business Wire·2 weeks ago
NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026
Business Wire·4 weeks ago
NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Neuropace stock?
Neuropace (NPCE) has a market cap of $465M as of March 18, 2026.
What is the P/E ratio for Neuropace stock?
The price to earnings (P/E) ratio for Neuropace (NPCE) stock is 0 as of March 18, 2026.
Does Neuropace stock pay dividends?
No, Neuropace (NPCE) stock does not pay dividends to its shareholders as of March 18, 2026.
When is the next Neuropace dividend payment date?
Neuropace (NPCE) stock does not pay dividends to its shareholders.
What is the beta indicator for Neuropace?
Neuropace (NPCE) has a beta rating of 1.87. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.